Car-NK cell therapy for lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a diagnosis of lupus that is still active despite treatment with steroids and at least one other lupus medication for at least 6 months
- Your lupus disease activity score is 8 or higher on the SLEDAI scale, which is a measure of lupus severity
- You have at least one organ system (like kidneys, skin, or joints) with moderate to severe inflammation, as measured by the BILAG system
- Your blood counts (neutrophils and hemoglobin) are within a safe range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
This trial tests a new type of cell treatment (BCMA-CD19 cCAR T cells) for people with lupus that has not responded well to standard therapies. It may help reduce lupus disease activity.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.